Genelux (GNLX) Shares Outstanding (2022 - 2026)
Genelux (GNLX) posted Shares Outstanding (Entity) of $44.8 million for Q1 2026, up 17.57% on a QoQ basis from $38.1 million in Q4 2025, and up 18.84% year-over-year from $37.7 million in Q1 2025.
Analysis
Genelux (GNLX) Shares Outstanding (2022 - 2026) Analysis & Trends
Genelux has reported Shares Outstanding (Entity) for 5 years, with the latest figure at $44.8 million in Q1 2026.
- On a quarterly basis, Shares Outstanding (Entity) rose 18.84% year-over-year to $44.8 million in Q1 2026; TTM through Mar 2026 was $44.8 million, a 18.84% increase from a year earlier, with the FY2025 full-year figure at $38.1 million, up 9.82% from the prior year.
- Shares Outstanding (Entity) was $44.8 million for Q1 2026 at Genelux, up from $38.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $44.8 million in Q1 2026, with the low at $9.1 million in Q1 2022.
- Average Shares Outstanding (Entity) over 5 years is $28.3 million, with a median of $30.8 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) jumped 193.52% in 2023, then grew 9.41% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $9.1 million in 2022, then surged by 193.52% to $26.8 million in 2023, then grew by 29.64% to $34.7 million in 2024, then gained by 9.82% to $38.1 million in 2025, then rose by 17.57% to $44.8 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $44.8 million (Q1 2026), $38.1 million (Q4 2025), and $38.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 720.78 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | 44.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 44.15 Mn |
| Dec 31, 2025 | 37.18 Mn |
| Sep 30, 2025 | 37.89 Mn |
| Jun 30, 2025 | 37.95 Mn |
| Mar 31, 2025 | 34.93 Mn |
| Dec 31, 2024 | 31.45 Mn |
| Sep 30, 2024 | 34.53 Mn |
| Jun 30, 2024 | 29.69 Mn |
| Mar 31, 2024 | 26.85 Mn |
| Dec 31, 2023 | 24.43 Mn |
| Sep 30, 2023 | 26.21 Mn |
| Jun 30, 2023 | 25.07 Mn |
| Mar 31, 2023 | 19.58 Mn |
| Dec 31, 2022 | 9.12 Mn |
| Sep 30, 2022 | 9.12 Mn |
| Mar 31, 2022 | 9.11 Mn |